However, safety and efficacy of these interventions have so far only been reported in vivo in Drosophila. Further studies in mouse models of FXTAS and C9ORF72-ALS/FTD will be necessary prior to validating or infirming these eIF4A co-factors as potential therapeutic targets. This evidence concerns the gene EIF4A2 and fragile X-associated tremor/ataxia syndrome.